<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138983</url>
  </required_header>
  <id_info>
    <org_study_id>OG67-STOP-study</org_study_id>
    <nct_id>NCT00138983</nct_id>
  </id_info>
  <brief_title>Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.</brief_title>
  <official_title>Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Health Care Insurance Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine wich treatment is the most effective in prevention
      of glucocorticoid-induced osteoporosis in patients with rheumatic diseases. The STOP-study: a
      randomized placebo controlled trial with alendronate versus alfacalcidol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with glucocorticoids (GCs) is associated with bone loss initiated already early in
      therapy, causing increased (vertebral) fracture risk. Bone loss is caused by inhibition of
      bone formation by GCs. Active vitamin D analogues like alfacalcidol directly stimulate
      osteoblasts leading to an increase in bone formation. Bisphosphonates like alendronate induce
      apoptosis of osteoclasts leading to inhibition of bone resorption.

      We performed a randomized, double-placebo, double-blind clinical trial of 18 months duration
      in patients with a rheumatic disease, starting GCs in a dosage of 7.5 mg prednisone
      equivalent daily or higher. Two hundred one patients were allocated to receive either
      alendronate 10 mg and alfacalcidol-placebo daily or alfacalcidol 1 microgram and
      alendronate-placebo daily. Primary outcome was change in bone mineral density of the lumbar
      spine in 18 months, secondary outcome incidence of (symptomatic) morphometric vertebral
      deformities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date>November 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in bone mineral density of the lumbar spine (lumbar vertebrae 2 to 4) at 18 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in bone mineral density of the femoral neck and total hip at 18 months and incidence of morphometrical vertebral deformities, symptomatic vertebral fractures and non-vertebral fractures.</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Polymyalgia Rheumatica</condition>
  <condition>Giant Cell Arteritis</condition>
  <condition>Polymyositis</condition>
  <condition>Wegenerâ€™s Granulomatosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate versus alfacalcidol (1-alpha OH vitamin D)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a rheumatic disease.

          -  Starting treatment with glucocorticoids in a dosage of 7.5 mg prednisone equivalent
             daily or higher.

          -  All ethnic groups and races.

        Exclusion Criteria:

          -  Glucocorticoid treatment in the past 12 months (except for 12 weeks preceding the
             study)

          -  Primary hyperparathyroidism, hyperthyroidism or hypothyroidism in last year

          -  Metabolic bone disease

          -  Creatinine clearance of &lt; 50 ml/min

          -  Documented hypercalcemia or hypercalciuria, nephrolithiasis in the last 5 years

          -  Pregnancy or lactation

          -  Treatment in the last 12 months with hormone-replacement therapy

          -  Anabolic steroids, calcitonin, active vitamin D3 analogues, fluoride or
             bisphosphonates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.W.J. Bijslma, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R.N.J.T.L. de Nijs, MD</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990 Mar 1;112(5):352-64. Review.</citation>
    <PMID>2407167</PMID>
  </reference>
  <reference>
    <citation>de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004 Aug;15(8):589-602. Epub 2004 May 7. Review.</citation>
    <PMID>15138667</PMID>
  </reference>
  <reference>
    <citation>Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292-9.</citation>
    <PMID>9682041</PMID>
  </reference>
  <results_reference>
    <citation>de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW; STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006 Aug 17;355(7):675-84.</citation>
    <PMID>16914703</PMID>
  </results_reference>
  <verification_date>March 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>November 28, 2006</last_update_submitted>
  <last_update_submitted_qc>November 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2006</last_update_posted>
  <keyword>glucocorticoid-induced osteoporosis</keyword>
  <keyword>rheumatic diseases</keyword>
  <keyword>prevention</keyword>
  <keyword>randomized double-blind, double placebo controlled trial</keyword>
  <keyword>alendronate versus alfacalcidol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Polymyositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

